Cover
Cover - shares | 3 Months Ended | |
Sep. 30, 2020 | Oct. 26, 2020 | |
Cover [Abstract] | ||
Entity Registrant Name | BIONOVATE TECHNOLOGIES CORP. | |
Entity Central Index Key | 0001575420 | |
Document Type | 10-Q | |
Amendment Flag | false | |
Current Fiscal Year End Date | --06-30 | |
Entity Small Business | true | |
Entity Shell Company | false | |
Entity Emerging Growth Company | false | |
Entity Current Reporting Status | Yes | |
Document Period End Date | Sep. 30, 2020 | |
Entity Filer Category | Non-accelerated Filer | |
Document Fiscal Period Focus | Q1 | |
Document Fiscal Year Focus | 2021 | |
Entity Common Stock Shares Outstanding | 59,423,598 | |
Document Quarterly Report | true | |
Document Transition Report | false | |
Entity Interactive Data Current | Yes |
BALANCE SHEETS
BALANCE SHEETS - USD ($) | Sep. 30, 2020 | Jun. 30, 2020 |
Current Assets | ||
Cash | $ 0 | $ 0 |
Total Current Assets | 0 | 0 |
TOTAL ASSETS | 0 | 0 |
Current Liabilities | ||
Accounts payable and accrued liabilities | 230,324 | 211,290 |
Due to related party | 3,840 | 0 |
Convertible notes payable | 185,375 | 185,375 |
Total Current Liabilities | 419,539 | 396,665 |
TOTAL LIABILITIES | 419,539 | 396,665 |
Stockholders' Deficit | ||
Preferred stock: 90,000,000 authorized; $0.0001 par value - no shares issued and outstanding | 0 | 0 |
Common stock: 100,000,000 authorized; $0.0001 par value 59,423,598 and 59,423,598 shares issued and outstanding | 5,942 | 5,942 |
Additional paid in capital | 2,295,633 | 2,295,633 |
Accumulated deficit | (2,721,114) | (2,698,240) |
Total Deficit | (419,539) | (396,665) |
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT | $ 0 | $ 0 |
BALANCE SHEETS (Parenthetical)
BALANCE SHEETS (Parenthetical) - $ / shares | Sep. 30, 2020 | Jun. 30, 2020 | Jun. 30, 2019 |
Stockholders' Deficit | |||
Preferred stock, shares par value | $ 0.0001 | $ 0.0001 | $ 0.0001 |
Preferred stock, shares authorized | 90,000,000 | 90,000,000 | 90,000,000 |
Preferred stock, shares issued | 0 | 0 | 0 |
Preferred stock, shares outstanding | 0 | 0 | 0 |
Common stock, shares par value | $ 0.0001 | $ 0.0001 | $ 0.0001 |
Common stock, shares authorized | 100,000,000 | 100,000,000 | 100,000,000 |
Common stock, shares issued | 59,423,598 | 59,423,598 | 59,423,598 |
Common stock, shares outstanding | 59,423,598 | 59,423,598 | 59,423,598 |
STATEMENT OF OPERATIONS (Unaudi
STATEMENT OF OPERATIONS (Unaudited) - USD ($) | 3 Months Ended | |
Sep. 30, 2020 | Sep. 30, 2019 | |
STATEMENT OF OPERATIONS (Unaudited) | ||
Revenues | $ 0 | $ 0 |
Operating Expenses | ||
Professional | 3,622 | 13,412 |
Total operating expenses | 3,622 | 13,412 |
Net loss from operations | (3,622) | (13,412) |
Other income (expense) | ||
Realized foreign currency gain | 0 | 68 |
Interest expense | (19,252) | (16,032) |
Total other expense | (19,252) | (15,964) |
Net loss before taxes | (22,874) | (29,376) |
Net loss | $ (22,874) | $ (29,376) |
Basic and dilutive loss per share | ||
Net loss | $ 0 | $ 0 |
Weighted average number of shares outstanding | 59,423,598 | 15,579,749 |
STATEMENT OF STOCKHOLDERS DEFIC
STATEMENT OF STOCKHOLDERS DEFICIT (Unaudited) - USD ($) | Total | Common Stock | Additional Paid-in Capital | Accumulated Deficit |
Balance, shares at Jun. 30, 2019 | 155,798 | |||
Balance, amount at Jun. 30, 2019 | $ (332,289) | $ 15 | $ 2,243,891 | $ (2,576,195) |
Beneficial conversion feature | 526 | 0 | 526 | 0 |
Net loss | (29,376) | $ 0 | 0 | (29,376) |
Balance, shares at Sep. 30, 2019 | 155,798 | |||
Balance, amount at Sep. 30, 2019 | (361,139) | $ 15 | 2,244,417 | (2,605,571) |
Balance, shares at Jun. 30, 2020 | 59,423,598 | |||
Balance, amount at Jun. 30, 2020 | (396,665) | $ 5,942 | 2,295,633 | (2,698,240) |
Net loss | (22,874) | |||
Net loss | (22,874) | $ 0 | 0 | (22,874) |
Balance, shares at Sep. 30, 2020 | 59,423,598 | |||
Balance, amount at Sep. 30, 2020 | $ (419,539) | $ 5,942 | $ 2,295,633 | $ (2,721,114) |
STATEMENT OF CASH FLOWS (Unaudi
STATEMENT OF CASH FLOWS (Unaudited) - USD ($) | 3 Months Ended | |
Sep. 30, 2020 | Sep. 30, 2019 | |
CASH FLOWS FROM OPERATING ACTIVITIES: | ||
Net loss | $ (22,874) | $ (29,376) |
Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | ||
Expenses paid by convertible notes | 0 | 526 |
Expenses paid by related party | 3,840 | 0 |
Amortization of debt discount | 0 | 526 |
Foreign currency adjustment | 0 | (68) |
Changes in operating assets and liabilities: | ||
Accounts payable and accrued liabilities | 19,034 | 28,392 |
Net cash provided by operating activities | 0 | 0 |
Net change in cash and cash equivalents | 0 | 0 |
Cash and cash equivalents, beginning of period | 0 | 0 |
Cash and cash equivalents, end of period | 0 | 0 |
Supplemental cash flow information | ||
Cash paid for interest | 0 | 0 |
Cash paid for taxes | 0 | 0 |
Non-cash transactions: | ||
Beneficial conversion feature | $ 0 | $ 526 |
NATURE AND CONTINUANCE OF OPERA
NATURE AND CONTINUANCE OF OPERATIONS | 3 Months Ended |
Sep. 30, 2020 | |
NATURE AND CONTINUANCE OF OPERATIONS | |
NOTE 1 - NATURE AND CONTINUANCE OF OPERATIONS | Bionovate Technologies Corp. (the “Company”, or the “Corporation”) was incorporated in the state of Nevada, United States on October 24, 2012 under the name MJP International Ltd. On December 1, 2017, the Company’s corporate name was changed to Bionovate Technologies Corp. The Corporation was formed and organized to capitalize on new opportunities found in the North American market for light-emitting diode (“LED”) lighting. With China as the manufacturing backbone of future LED products, the Corporation has set up an office in Guangzhou, China in search of high-quality products offered by reputable manufacturers to be introduced to Canada, the United States, and abroad. The Corporation has set out further details of the acquisition below as well as in Notes 3 and 4 to these consolidated financial statements. On October 7, 2020, Bionovate Technologies Corp. (the “Company”) entered into a Share Exchange Agreement (the “Share Exchange Agreement”) facilitated between Evergreen Solutions, Ltd, a private Company (“Evergreen”), and Human Data AG, a private Switzerland Company (“Human Data”). Pursuant to the Share Exchange Agreement, in exchange for the acquisition of all of the outstanding Company shares which Evergreen owns, to wit, 54,270,000 shares (the “Exchange Shares”), the Company will receive 12,500 shares of Digital Diagnostics AG (“Digital”) owned by Human Data, which equates to 25% of the currently issued shares of Digital. The Share Exchange Agreement contains customary representations and warranties made by the Company, on the one hand, and Evergreen and Human Data on the other hand, made solely for the benefit of the other, which in certain cases are subject to specified exceptions and qualifications contained in the Share Exchange Agreement or in information provided pursuant to certain disclosure schedules to the Share Exchange Agreement GOING CONCERN The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern. However, the Company has an accumulated deficit at September 30, 2020 of $2,721,114, is in a net liability position and needs cash to maintain its operations. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company’s continued existence is dependent upon management’s ability to develop profitable operations, continued contributions from the Company’s executive officers to finance its operations and the ability to obtain additional funding sources to explore potential strategic relationships and to provide capital and other resources for the further development and marketing of the Company’s products and business. |
SUMMARY OF SIGNIFICANT ACCOUNTI
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | 3 Months Ended |
Sep. 30, 2020 | |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | |
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | Basis of Presentation The accompanying unaudited financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions for Form 10-Q and Article 210 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. All such adjustments are of a normal recurring nature. Operating results for the three months ended September 30, 2020, are not necessarily indicative of the results that may be expected for the fiscal year ending June 30, 2021. For further information, refer to the financial statements and footnotes thereto included in the Corporation’s filed Form 10-K for the year ended June 30, 2020. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect application of policies and the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the year. Actual results could differ from these estimates. Estimates and their underlying assumptions are reviewed on an ongoing basis. Changes in estimates are recorded in the accounting period in which they are determined. The critical accounting estimates and assumptions in the accompanying unaudited condensed interim financial statements include the provision for unpaid loss and loss adjustment expenses which may result from product warranty provisions; valuation of deferred income taxes; valuation and impairment assessment of intangible assets; goodwill recoverability; and deferred acquisition costs. Fair Value of Financial Instrument The Corporation follows FASB ASC 820, Fair Value Measurements and Disclosures, for all financial instruments and non-financial instruments accounted for at fair value on a recurring basis. This new accounting standard establishes a single definition of fair value and a framework for measuring fair value, sets out a fair value hierarchy to be used to classify the source of information used in fair value measurement and expands disclosures about fair value measurements required under other accounting pronouncements. It does not change existing guidance as to whether or not an instrument is carried at fair value. The Corporation defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities, which are required to be recorded at fair value, the Corporation considers the principal or most advantageous market in which the Corporation would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as inherent risk, transfer restrictions and credit risk. The Corporation applies FASB ASC 825, Financial Instruments, which allows companies to choose to measure eligible financial instruments and certain other items at fair value that are not required to be measured at fair value. The Corporation has not elected the fair value option for any eligible financial instruments. Basic and Diluted Loss per Common Stock FASB ASC 260 requires dual presentation of basic and diluted earnings per share (EPS) with a reconciliation of the numerator and denominator of the EPS computations. Basic earnings per share amounts are based on the weighted average shares of common stock outstanding. If applicable, diluted earnings per stock would assume the conversion, exercise or issuance of all potential common stock instruments such as options, warrants and convertible securities, unless the effect is to reduce a loss or increase earnings per share. Diluted net income (loss) per common stock on the potential exercise of the equity-based financial instruments is not presented where anti-dilutive. For the three months ended September 30, 2020 and 2019, the following common stock equivalents were excluded from the computation of diluted net loss per share as the result of the computation was anti-dilutive. September 30, September 30, 2020 2019 (shares) (shares) Convertible notes 26,740,500 24,575,800 |
ACCOUNTS PAYABLE AND ACCRUED LI
ACCOUNTS PAYABLE AND ACCRUED LIABILITEIS | 3 Months Ended |
Sep. 30, 2020 | |
ACCOUNTS PAYABLE AND ACCRUED LIABILITEIS | |
NOTE 3 - ACCOUNTS PAYABLE AND ACCRUED LIABILITEIS | AS of September 30, 2020, and June 30, 2020, accounts payable and accrued liabilities consisted of as follows, September 30, June 30, 2020 2020 Accounts payable $ 38,138 $ 25,702 Accrued expenses - 12,654 Accrued interest 151,161 131,909 Due to a former related party 41,025 41,025 $ 230,324 $ 211,290 |
CONVERTIBLE NOTE
CONVERTIBLE NOTE | 3 Months Ended |
Sep. 30, 2020 | |
CONVERTIBLE NOTE | |
NOTE 4 - CONVERTIBLE NOTE | Convertible notes payable at September 30, 2020 and June 30,2020, consists of the following: September 30, June 30, 2020 2020 Dated November 1, 2016 $ 4,439 $ 4,439 Dated January 1, 2017 - 1 - - Dated January 1, 2017 - 2 - - Dated June 30, 2017 9,969 9,969 Dated April 1, 2018 - 1 10,000 10,000 Dated April 1, 2018 - 2 10,000 10,000 Dated June 30, 2018 28,376 28,376 Dated July 5, 2018 - 1 30,000 30,000 Dated July 5, 2018 - 2 15,000 15,000 Dated July 5, 2018 - 3 15,000 15,000 Dated December 31, 2018 17,302 17,302 Dated March 31, 2019 1,000 1,000 Dated June 30, 2019 17,037 17,037 Dated September 30, 2019 526 526 Dated December 31, 2019 18,892 18,892 Dated March 31, 2020 5,834 5,834 Dated June 30, 2020 2,000 2,000 Total convertible notes payable 185,375 185,375 Less: Unamortized debt discount - - Total convertible notes 185,375 185,375 Less: current portion of convertible notes 185,375 185,375 Long-term convertible notes $ - $ - For the three months ended September 30, 2020 and 2019, the Company recognized interest expense of $19,252 and $15,506 and amortization of discount, included in interest expense, of $0 and $526, respectively. As of September 30, 2020, and June 30, 2020, the Company recorded accrued interest of $151,161 and $131,909, respectively Dated November 1, 2016 On November 1, 2016, the Company issued a convertible note with a conversion price of $0.005 to extinguish debt of $18,239. The convertible note is unsecured, bears interest at 4% per annum and due and payable on November 1, 2017. The Company recorded a discount on the convertible note due to a beneficial conversion feature of $18,239. Dated June 30, 2017 On June 30, 2017, the Company issued a convertible note with a conversion price of $0.01 to pay operating expenses of $9,969. The convertible note is unsecured, bears interest at 35% per annum, has no maturity date and due on demand. The Company recorded a discount on the convertible note due to a beneficial conversion feature of $9,969. Dated April 1, 2018 – 1 and 2 On April 1, 2018, the Company issued 2 convertible notes totaling of $20,000 with a conversion price of $$0.01 to pay a purchase of a patent of $10,000. The convertible note is unsecured, bears interest at 45% per annum, has no maturity date and is due on demand. The Company recorded a discount on the convertible note due to a beneficial conversion feature of $20,000. Dated June 30, 2018 On June 30, 2018, the Company issued a convertible note with a conversion price of $0.01 to pay operating expenses of $28,376. The convertible note is unsecured, bears interest at 30% per annum, has no maturity date and is due on demand. The Company recorded a discount on the convertible note due to a beneficial conversion feature of $28,376. Dated July 5, 2018 – 1, 2 and 3 On June 30, 2018, the Company issued 3 convertible notes totaling of $60,000 with a conversion price of $0.01 to extinguish amounts due to related parties of $145,523. The convertible notes are unsecured, bears interest at 30% per annum, has no maturity date and is due on demand. The Company recorded a discount on the convertible notes due to a beneficial conversion feature of $60,000. Dated December 31, 2018 On December 31, 2018, the Company issued a convertible note with a conversion price of $0.005 to pay operating expenses of $17,302. The convertible note is unsecured, bears interest at 35% per annum, has no maturity date and is due on demand. The Company recorded a discount on the convertible notes due to a beneficial conversion feature of $17,302. Dated March 31, 2019 On March 31, 2019, the Company issued a convertible note with a conversion price of $0.01 to pay operating expenses of $6,427. The convertible note is unsecured, bears interest at 20% per annum, has no maturity date and is due on demand. The Company recorded a discount on the convertible notes due to a beneficial conversion feature of $6,427. Effective January 28, 2020, the Company amended a convertible note. The Note reduces the interest rate from 20% to 0 and changes the conversion price from $0.01 to $0.0001. Effective January 28, 2020, the Note of $6,427 was assigned to Evergreen Solutions Ltd., and $5,427 was immediately converted for the issuance of 54,270,000 shares of common stock of the Company resulting in a change of control. Dated June 30, 2019 On June 30, 2019, the Company issued a convertible note with a conversion price of $0.005 to pay operating expenses of $17,037. The convertible note is unsecured, bears interest at 35% per annum, has no maturity date and is due on demand. The Company recorded a discount on the convertible notes due to a beneficial conversion feature of $17,037. Dated September 30, 2019 On September 30, 2019, the Company issued a convertible note with a conversion price of $0.005 to pay operating expenses of $526. The convertible note is unsecured, bears interest at 35% per annum, has no maturity date and is due on demand. The Company recorded a discount on the convertible notes due to a beneficial conversion feature of $526. Dated December 31, 2019 On December 31, 2019, the Company issued a convertible note with a conversion price of $0.005 to pay operating expenses of $18,892. The convertible note is unsecured, bears interest at 35% per annum, has no maturity date and is due on demand. The Company recorded a discount on the convertible notes due to a beneficial conversion feature of $18,892. Dated March 31, 2020 On March 31, 2020, the Company issued a convertible note with a conversion price of $0.005 to pay operating expenses of $5,834. The convertible note is unsecured, bears interest at 35% per annum, has no maturity date and is due on demand. The Company recorded a discount on the convertible notes due to a beneficial conversion feature of $5,834. Dated June 30, 2020 On June 30, 2020, the Company issued a convertible note with a conversion price of $0.001 to pay operating expenses of $2,000. The convertible note is unsecured, bears interest at 35% per annum, has no maturity date and is due on demand. The Company recorded a discount on the convertible notes due to a beneficial conversion feature of $2,000. |
RELATED PARTY TRANSACTIONS
RELATED PARTY TRANSACTIONS | 3 Months Ended |
Sep. 30, 2020 | |
RELATED PARTY TRANSACTIONS | |
NOTE 5 - RELATED PARTY TRANSACTIONS | During the three months ended September 30, 2020, the Company’s sole officer paid $3,840 for operating expenses on behalf of the Company. As of September 30, 2020, the Company was obligated to the officer, for an unsecured, non-interest-bearing demand loan with a balance of $3,840. |
EQUITY
EQUITY | 3 Months Ended |
Sep. 30, 2020 | |
EQUITY | |
NOTE 6 - EQUITY | Preferred Stock The Company is authorized to issue 90,000,000 shares of preferred stock at a par value of $0.0001. No shares were issued and outstanding as of September 30, 2020 and June 30,2020, respectively. Common Stock The Company is authorized to issue 100,000,000 shares of preferred stock at a par value of $0.0001. As at September 30, 2020 and June 30, 2020, 59,423,598 shares of common stock were issued and outstanding. As at September 30, 2020, there were no warrants or options outstanding. |
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS | 3 Months Ended |
Sep. 30, 2020 | |
SUBSEQUENT EVENTS | |
NOTE 7 - SUBSEQUENT EVENTS | Management has evaluated subsequent events through the date these financial statements were available to be issued. Based on our evaluation no material events have occurred that require disclosure. |
SUMMARY OF SIGNIFICANT ACCOUN_2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) | 3 Months Ended |
Sep. 30, 2020 | |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | |
Basis Of Presentation | The accompanying unaudited financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions for Form 10-Q and Article 210 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. All such adjustments are of a normal recurring nature. Operating results for the three months ended September 30, 2020, are not necessarily indicative of the results that may be expected for the fiscal year ending June 30, 2021. For further information, refer to the financial statements and footnotes thereto included in the Corporation’s filed Form 10-K for the year ended June 30, 2020. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect application of policies and the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the year. Actual results could differ from these estimates. Estimates and their underlying assumptions are reviewed on an ongoing basis. Changes in estimates are recorded in the accounting period in which they are determined. The critical accounting estimates and assumptions in the accompanying unaudited condensed interim financial statements include the provision for unpaid loss and loss adjustment expenses which may result from product warranty provisions; valuation of deferred income taxes; valuation and impairment assessment of intangible assets; goodwill recoverability; and deferred acquisition costs. |
Fair Value of Financial Instrument | The Corporation follows FASB ASC 820, Fair Value Measurements and Disclosures, for all financial instruments and non-financial instruments accounted for at fair value on a recurring basis. This new accounting standard establishes a single definition of fair value and a framework for measuring fair value, sets out a fair value hierarchy to be used to classify the source of information used in fair value measurement and expands disclosures about fair value measurements required under other accounting pronouncements. It does not change existing guidance as to whether or not an instrument is carried at fair value. The Corporation defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities, which are required to be recorded at fair value, the Corporation considers the principal or most advantageous market in which the Corporation would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as inherent risk, transfer restrictions and credit risk. The Corporation applies FASB ASC 825, Financial Instruments, which allows companies to choose to measure eligible financial instruments and certain other items at fair value that are not required to be measured at fair value. The Corporation has not elected the fair value option for any eligible financial instruments. |
Basic and Diluted Loss per Common Stock | FASB ASC 260 requires dual presentation of basic and diluted earnings per share (EPS) with a reconciliation of the numerator and denominator of the EPS computations. Basic earnings per share amounts are based on the weighted average shares of common stock outstanding. If applicable, diluted earnings per stock would assume the conversion, exercise or issuance of all potential common stock instruments such as options, warrants and convertible securities, unless the effect is to reduce a loss or increase earnings per share. Diluted net income (loss) per common stock on the potential exercise of the equity-based financial instruments is not presented where anti-dilutive. For the three months ended September 30, 2020 and 2019, the following common stock equivalents were excluded from the computation of diluted net loss per share as the result of the computation was anti-dilutive. September 30, September 30, 2020 2019 (shares) (shares) Convertible notes 26,740,500 24,575,800 |
SUMMARY OF SIGNIFICANT ACCOUN_3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) | 3 Months Ended |
Sep. 30, 2020 | |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) | |
Schedule of diluted net loss per share | September 30, September 30, 2020 2019 (shares) (shares) Convertible notes 26,740,500 24,575,800 |
ACCOUNTS PAYABLE AND ACCRUED _2
ACCOUNTS PAYABLE AND ACCRUED LIABILITEIS (Tables) | 3 Months Ended |
Sep. 30, 2020 | |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) | |
Schedule of accounts payable and accrued liabilities | September 30, June 30, 2020 2020 Accounts payable $ 38,138 $ 25,702 Accrued expenses - 12,654 Accrued interest 151,161 131,909 Due to a former related party 41,025 41,025 $ 230,324 $ 211,290 |
CONVERTIBLE NOTE (Tables)
CONVERTIBLE NOTE (Tables) | 3 Months Ended |
Sep. 30, 2020 | |
CONVERTIBLE NOTE | |
Schedule of convertible note payable | September 30, June 30, 2020 2020 Dated November 1, 2016 $ 4,439 $ 4,439 Dated January 1, 2017 - 1 - - Dated January 1, 2017 - 2 - - Dated June 30, 2017 9,969 9,969 Dated April 1, 2018 - 1 10,000 10,000 Dated April 1, 2018 - 2 10,000 10,000 Dated June 30, 2018 28,376 28,376 Dated July 5, 2018 - 1 30,000 30,000 Dated July 5, 2018 - 2 15,000 15,000 Dated July 5, 2018 - 3 15,000 15,000 Dated December 31, 2018 17,302 17,302 Dated March 31, 2019 1,000 1,000 Dated June 30, 2019 17,037 17,037 Dated September 30, 2019 526 526 Dated December 31, 2019 18,892 18,892 Dated March 31, 2020 5,834 5,834 Dated June 30, 2020 2,000 2,000 Total convertible notes payable 185,375 185,375 Less: Unamortized debt discount - - Total convertible notes 185,375 185,375 Less: current portion of convertible notes 185,375 185,375 Long-term convertible notes $ - $ - |
NATURE AND CONTINUANCE OF OPE_2
NATURE AND CONTINUANCE OF OPERATIONS (Details Narrative) - USD ($) | 1 Months Ended | ||
Oct. 07, 2020 | Sep. 30, 2020 | Jun. 30, 2020 | |
Accumulated deficit | $ (2,721,114) | $ (2,698,240) | |
Digital Diagnostics AG [Member] | Evergreen Solutions Ltd. [Member] | Share Exchange Agreement [Member] | |||
Acqusition of shares, amount | $ 12,500 | ||
Percentage of shares acquired | 25.00% | ||
Acqusition of shares | 54,270,000 |
SUMMARY OF SIGNIFICANT ACCOUN_4
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details ) - shares | 3 Months Ended | |
Sep. 30, 2020 | Sep. 30, 2019 | |
NATURE AND CONTINUANCE OF OPERATIONS | ||
Convertible notes | 26,740,500 | 24,575,800 |
ACCOUNTS PAYABLE AND ACCRUED _3
ACCOUNTS PAYABLE AND ACCRUED LIABILITEIS (Details) - USD ($) | Sep. 30, 2020 | Jun. 30, 2020 |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) | ||
Accounts payable | $ 38,138 | $ 25,702 |
Accrued expense | 0 | 12,654 |
Accrued interest | 151,161 | 131,909 |
Due to a former related party | 41,025 | 41,025 |
Total | $ 230,324 | $ 211,290 |
CONVERTIBLE NOTE (Details)
CONVERTIBLE NOTE (Details) - USD ($) | Sep. 30, 2020 | Jun. 30, 2020 | Jan. 28, 2020 |
Total convertible notes payable | $ 185,375 | $ 185,375 | |
Less: Unamortized debt discount | 0 | 0 | |
Total convertible notes | 185,375 | 185,375 | |
Less: current portion of convertible notes | 185,375 | 185,375 | |
Long-term convertible notes | 0 | 0 | |
November 1, 2016 [Member] | Convertible Notes Payable [Member] | |||
Total convertible notes payable | 4,439 | 4,439 | |
January 1, 2017 - 1 [Member] | Convertible Notes Payable [Member] | |||
Total convertible notes payable | 0 | 0 | |
January 1, 2017 - 2 [Member] | Convertible Notes Payable [Member] | |||
Total convertible notes payable | 0 | 0 | |
June 30, 2017 [Member] | Convertible Notes Payable [Member] | |||
Total convertible notes payable | 9,969 | 9,969 | |
April 1, 2018 - 1 [Member] | Convertible Notes Payable [Member] | |||
Total convertible notes payable | 10,000 | 10,000 | |
April 1, 2018 - 2 [Member] | Convertible Notes Payable [Member] | |||
Total convertible notes payable | 10,000 | 10,000 | |
June 30, 2018 [Member] | Convertible Notes Payable [Member] | |||
Total convertible notes payable | 28,376 | 28,376 | |
July 5, 2018 - 1 [Member] | Convertible Notes Payable [Member] | |||
Total convertible notes payable | 30,000 | 30,000 | |
July 5, 2018 - 2 [Member] | Convertible Notes Payable [Member] | |||
Total convertible notes payable | 15,000 | 15,000 | |
July 5, 2018 - 3 [Member] | Convertible Notes Payable [Member] | |||
Total convertible notes payable | 15,000 | 15,000 | |
December 31, 2018 [Member] | Convertible Notes Payable [Member] | |||
Total convertible notes payable | 17,302 | 17,302 | |
March 31, 2019 [Member] | Convertible Notes Payable [Member] | |||
Total convertible notes payable | 6,427 | 1,000 | $ 6,427 |
June 30, 2019 [Member] | Convertible Notes Payable [Member] | |||
Total convertible notes payable | 17,037 | 17,037 | |
September 30, 2019 [Member] | Convertible Notes Payable [Member] | |||
Total convertible notes payable | 526 | 526 | |
December 31, 2019 [Member] | Convertible Notes Payable [Member] | |||
Total convertible notes payable | 18,892 | 18,892 | |
March 31, 2020 [Member] | Convertible Notes Payable [Member] | |||
Total convertible notes payable | 5,834 | 5,834 | |
June 30, 2020 [Member] | Convertible Notes Payable [Member] | |||
Total convertible notes payable | $ 2,000 | $ 2,000 |
CONVERTIBLE NOTE (Details Narra
CONVERTIBLE NOTE (Details Narrative) - USD ($) | 1 Months Ended | 3 Months Ended | ||
Jan. 28, 2020 | Sep. 30, 2020 | Sep. 30, 2019 | Jun. 30, 2020 | |
Interest expenses | $ 19,252 | $ 15,506 | ||
Amortization of debt discount | 0 | 526 | ||
Accrued interest | $ 151,161 | $ 131,909 | ||
Beneficial conversion feature | $ 526 | |||
Common stock shares issued upon conversion of debt, shares | 26,740,500 | 24,575,800 | ||
Convertible Notes payable | $ 185,375 | 185,375 | ||
Evergreen Solutions Ltd. [Member] | ||||
Common stock shares issued upon conversion of debt, shares | 54,270,000 | |||
November 1, 2016 [Member] | Convertible Notes Payable [Member] | ||||
Convertible note conversion price | $ 0.005 | |||
Extinguisment of debt | $ 18,239 | |||
Beneficial conversion feature | $ 18,239 | |||
Convertible note bearing interest | 4.00% | |||
Maturity date | Nov. 1, 2017 | |||
Convertible Notes payable | $ 4,439 | 4,439 | ||
June 30, 2017 [Member] | Convertible Notes Payable [Member] | ||||
Convertible note conversion price | $ 0.01 | |||
Beneficial conversion feature | $ 9,969 | |||
Convertible note bearing interest | 35.00% | |||
Operating expenses | $ 9,969 | |||
Convertible Notes payable | $ 9,969 | 9,969 | ||
June 30, 2018 [Member] | Convertible Notes Payable [Member] | ||||
Convertible note conversion price | $ 0.01 | |||
Beneficial conversion feature | $ 28,376 | |||
Convertible note bearing interest | 30.00% | |||
Operating expenses | $ 28,376 | |||
Convertible Notes payable | 28,376 | 28,376 | ||
July 5, 2018 - 1 [Member] | Convertible Notes Payable [Member] | ||||
Debt conversion, converted instrument, principal amount | $ 60,000 | |||
Convertible note conversion price | $ 0.001 | |||
Extinguisment of debt | $ 145,523 | |||
Beneficial conversion feature | 60,000 | |||
Convertible Notes payable | $ 30,000 | 30,000 | ||
December 31, 2018 [Member] | Convertible Notes Payable [Member] | ||||
Convertible note conversion price | $ 0.005 | |||
Beneficial conversion feature | $ 17,302 | |||
Convertible note bearing interest | 35.00% | |||
Operating expenses | $ 17,302 | |||
Convertible Notes payable | $ 17,302 | 17,302 | ||
March 31, 2019 [Member] | Convertible Notes Payable [Member] | ||||
Debt conversion, converted instrument, principal amount | $ 5,427 | |||
Convertible note conversion price | $ 0.0001 | $ 0.01 | ||
Beneficial conversion feature | $ 6,427 | $ 6,427 | ||
Convertible note bearing interest | 0.00% | 20.00% | ||
Convertible Notes payable | $ 6,427 | $ 6,427 | 1,000 | |
June 30, 2019 [Member] | Convertible Notes Payable [Member] | ||||
Convertible note conversion price | $ 0.005 | |||
Beneficial conversion feature | $ 17,037 | |||
Convertible note bearing interest | 35.00% | |||
Operating expenses | $ 17,037 | |||
Convertible Notes payable | $ 17,037 | 17,037 | ||
September 30, 2019 [Member] | Convertible Notes Payable [Member] | ||||
Convertible note conversion price | $ 0.005 | |||
Beneficial conversion feature | $ 526 | |||
Convertible note bearing interest | 35.00% | |||
Operating expenses | $ 526 | |||
Convertible Notes payable | $ 526 | 526 | ||
December 31, 2019 [Member] | Convertible Notes Payable [Member] | ||||
Convertible note conversion price | $ 0.005 | |||
Beneficial conversion feature | $ 18,892 | |||
Convertible note bearing interest | 35.00% | |||
Operating expenses | $ 18,892 | |||
Convertible Notes payable | $ 18,892 | 18,892 | ||
March 31, 2020 [Member] | Convertible Notes Payable [Member] | ||||
Convertible note conversion price | $ 0.005 | |||
Beneficial conversion feature | $ 5,834 | |||
Convertible note bearing interest | 35.00% | |||
Operating expenses | $ 5,834 | |||
Convertible Notes payable | $ 5,834 | 5,834 | ||
June 30, 2020 [Member] | Convertible Notes Payable [Member] | ||||
Convertible note conversion price | $ 0.001 | |||
Beneficial conversion feature | $ 2,000 | |||
Convertible note bearing interest | 35.00% | |||
Operating expenses | $ 2,000 | |||
Convertible Notes payable | $ 2,000 | $ 2,000 | ||
April 1, 2018 - 1 and 2 [Member] | Convertible Notes Payable [Member] | ||||
Convertible note conversion price | $ 0.01 | |||
Beneficial conversion feature | $ 20,000 | |||
Convertible note bearing interest | 45.00% | |||
Convertible promissory note | $ 20,000 | |||
Patent purchase | $ 10,000 |
RELATED PARTY TRANSACTIONS (Det
RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($) | 3 Months Ended | |
Sep. 30, 2020 | Sep. 30, 2019 | |
RELATED PARTY TRANSACTIONS (Details Narrative) | ||
Operating expenses | $ 3,622 | $ 13,412 |
Non-interest-bearing loan | $ 3,840 |
EQUITY (Details Narrative)
EQUITY (Details Narrative) - $ / shares | Sep. 30, 2020 | Jun. 30, 2020 | Jun. 30, 2019 |
EQUITY (Details Narrative) | |||
Preferred stock, shares authorized | 90,000,000 | 90,000,000 | 90,000,000 |
Preferred stock, par value | $ 0.0001 | $ 0.0001 | $ 0.0001 |
Preferred stock, shares issued | 0 | 0 | 0 |
Preferred stock, shares outstanding | 0 | 0 | 0 |
Common stock, shares authorized | 100,000,000 | 100,000,000 | 100,000,000 |
Common stock, shares par value | $ 0.0001 | $ 0.0001 | $ 0.0001 |
Common stock, shares issued | 59,423,598 | 59,423,598 | 59,423,598 |
Common stock, shares outstanding | 59,423,598 | 59,423,598 | 59,423,598 |